Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield Maine Clinical UM PPO Prior…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - MainePolicy N/A

    Clinical UM PPO Guidelines (California) — Clinical Utilization Management Guidance (index of guideline entries)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Maine policy alerts

    Know when Blue Cross Blue Shield - Maine releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    An index compilation of Clinical Utilization Management (UM) PPO guideline titles and control numbers used to indicate which clinical guideline documents and programs govern precertification and review processes for covered services for local fully‑insured and select ASO groups (excludes BlueCard, Medicare/Medicaid, Medicare Supplement, and FEP).

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerBlue Cross Blue Shield - Maine
    PolicyClinical UM PPO Guidelines (California) — index of clinical guideline entries
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain precertification (prior authorization) when required and contact the phone number on the member's ID card to confirm precertification requirements.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100+listed clinical guideline entries in this partial document
    applies toapplies to
    examplesspecialty drug/therapy examples
    Excludesexcludes
    Stage 3–4biomarker testing PA exemption

    Coverage Criteria & Scope

    Applicability and use of CG entries

    This document segment provides listings of drug-specific clinical guideline (CG) entries which are used to determine coverage and prior authorization for the listed drugs under California PPO when the Pre-Payment Review Program applies.

    Applicability: Applies to local fully‑insured Anthem Blue Cross members and select members covered under self‑insured (ASO) benefit plans when services are medically managed as part of a purchased program.

    If the Pre‑Payment Review Program has not been purchased by the account, precertification is not required and clinical review will not be performed.

    Guideline listings and prior authorization applicability

    Guideline list and administrative/prior authorization applicability

    Guideline listings: The document enumerates clinical guideline (CG) numbers and titles (Anthem Clinical UM and Carelon Clinical Appropriateness Guidelines) that govern clinical appropriateness determinations for the listed services and specialty pharmaceuticals.

    Providers should reference the specific CG number when submitting authorization requests; detailed clinical criteria and any step‑therapy requirements are contained within each referenced CG document.

    Prior authorization applicability: Prior authorization (precertification) requirements may apply for services governed by the listed CGs for select accounts and purchased programs.

    Providers will be notified upon requesting precertification if prior authorization is required for the member. Effective July 1, 2022, prior authorization is no longer required for biomarker testing for members with advanced or metastatic stage 3 or 4 cancer; post‑service medical necessity review for such biomarker testing is not permitted (only confirmation of stage 3 or 4 is allowed).

    Carelon guidelines referenced: In addition to Anthem Clinical UM Guidelines, the health plan uses Carelon Clinical Appropriateness Guidelines (cardiology, genetic testing, radiology, radiation oncology, surgical site‑of‑care, sleep, musculoskeletal, etc.) as noted; select Carelon guidelines are used for prior authorization review for specified accounts.

    Carelon guideline web links and specific CG numbers are listed in the document for provider reference.

    This section of the Clinical UM PPO Guidelines does not apply to members covered by BlueCard®, Medicare Advantage, Medicaid, Medicare Supplement, or the Federal Employee Program® (FEP®). It applies to local fully‑insured Anthem Blue Cross members and select members covered under self‑insured (ASO) benefit plans when services are medically managed as part of a purchased program. If the Pre‑Payment Review Program or similar purchased program has not been obtained by the account, precertification is not required and clinical review will not be performed. Providers should contact the phone number on the back of the member ID card for information about precertification requirements and notification.

    This document fragment reiterates that the listed Clinical UM PPO guideline entries apply to local fully‑insured and select ASO members and do not apply to BlueCard®, Medicare Advantage, Medicaid, Medicare Supplement, or FEP® members. The provider will be notified when requesting precertification if precertification is required for the member; if the program has not been purchased, precertification is not required and clinical review will not be performed.

    This extract is an index of Clinical Guideline (CG) titles and CG numbers for California PPO and contains listings of drug‑ and procedure‑specific guideline entries. It does not include granular coverage criteria in this fragment; each listed CG title corresponds to a separate guideline document that should be referenced for specific coverage and authorization rules.

    Alternate listing in this file shows additional CG titles and numbers (drug names such as Danyelza, Oxlumo, Margenza/Breyanzi and others). As above, these entries serve as an index; no standalone coverage criteria or exclusions are provided in this fragment and providers should consult the individual CG for authorization requirements.

    A variant of the exclusions statement appears elsewhere in the index confirming that these guideline listings do not apply to BlueCard®, Medicare Advantage, Medicaid, Medicare Supplement, or FEP® members. The provider will be notified when requesting precertification if precertification is required; if the account has not purchased the applicable program, precertification and clinical review will not be performed.

    Effective July 1, 2022, in compliance with California law, the plan and its delegated entities will not require prior authorization for biomarker testing for members with advanced or metastatic stage 3 or 4 cancer. Post‑service review of medical necessity for biomarker testing in these members is not permitted; only confirmation of advanced or metastatic stage 3 or 4 cancer is allowed when performing post‑service review.

    Clinical Guideline Index & Codes

    Listed CG Numbers and associated drug titles in this segmentmixed
    CC-0174Kesimpta (ofatumumab) / Proleukin (aldesleukin) — listed CG number
    CC-0175Kesimpta (ofatumumab) / Proleukin (aldesleukin) — listed CG number
    CC-0176Beleodaq (belinostat) — listed CG number
    CC-0178Zilretta (triamcinolone acetonide extended-release) / Synribo (omacetaxine mepesuccinate) — listed CG number
    CC-0180Monjuvi (tafasitamab-cxix) / Veklury (remdesivir) — listed CG number
    CC-0182Iron Agents — listed CG number
    CC-0183Sogroya (somapacitan-beco) — listed CG number
    CC-0187Margenza (margetuximab-cmkb) / Breyanzi (lisocabtagene maraleucel) — listed CG number
    CC-0188Margenza (margetuximab-cmkb) / Breyanzi (lisocabtagene maraleucel) — listed CG number
    CC-0192Cosela (trilaciclib) — listed CG number
    1–10 of 18
    1/2
    Referenced CG numbers in fragmentmixed
    CC-0187CG number referenced in listing
    CC-0188CG number referenced in listing
    CC-0192CG number referenced in listing
    CC-0193CG number referenced in listing
    CC-0194CG number referenced in listing
    CC-0195CG number referenced in listing
    CC-0196CG number referenced in listing
    CC-0197CG number referenced in listing
    CC-0199CG number referenced in listing
    CC-0200CG number referenced in listing
    1–10 of 70
    1/7
    Specialty drug CG numbers referencedmixed
    CC-0263CG number referenced for Imdelitra (tartlatamab-dlle) / Anktiva (nogapendekin alfa inbekicept-pmln)
    CC-0264CG number referenced for Imdelitra (tartlatamab-dlle) / Anktiva (nogapendekin alfa inbekicept-pmln)
    CC-0262CG number referenced in listings alongside CC-0263 CC-0264
    Listed clinical guideline codes and titlesmixed
    CG-MED-19Custodial Care
    CG-MED-26Neonatal Levels of Care
    CG-MED-64Transcatheter Ablation of Arrhythmogenic Foci in the Pulmonary Veins
    CG-MED-65Manipulation Under Anesthesia
    CG-MED-69Inhaled Nitric Oxide
    CG-MED-73Hyperbaric Oxygen Therapy (Systemic/Topical)
    CG-MED-74Implantable Ambulatory Event Monitors and Mobile Cardiac Telemetry
    CG-MED-81High Intensity Focused Ultrasound (HIFU) for Oncologic Indications
    CG-MED-83Site of Care: Specialty Pharmaceuticals
    CG-MED-88Preimplantation Embryo Biopsy
    1–10 of 36
    1/4
    Listed Clinical Guidelines and Carelon guideline referencesmixed
    CG-SURG-71Reduction Mammaplasty
    CG-SURG-76Carotid, Vertebral and Intracranial Artery Stent Placement with or without Angioplasty
    CG-SURG-78Locoregional and Surgical Techniques for Treating Primary and Metastatic Liver Malignancies
    CG-SURG-79Implantable Infusion Pumps
    CG-SURG-81Cochlear Implants and Auditory Brainstem Implants
    CG-SURG-83Reduction Mammaplasty (entry repeats contexts)
    CG-SURG-84Bariatric Surgery and Other Treatments for Clinically Severe Obesity
    CG-SURG-88Mandibular/Maxillary (Orthognathic) Surgery
    CG-SURG-95Mastectomy for Gynecomastia
    CG-SURG-96Sacral Nerve Stimulation and Percutaneous Tibial Nerve Stimulation for Urinary and Fecal Incontinence; Urinary Retention
    1–10 of 31
    1/4
    Cancer stage for biomarker testing PA exemption
    Cancer stage for PA exemptionAdvanced or metastatic (stage 3 or 4) — no prior authorization required for biomarker testing for these members (effective July 1, 2022).
    Post-service review limitationPost‑service medical necessity review for biomarker testing in members with advanced or metastatic stage 3 or 4 cancer is not permitted; only confirmation of stage 3 or 4 is allowed.
    Applicable test typeBiomarker testing, including testing for cancer progression and recurrence.

    Precertification, Prior Authorization & Provider Notices

    Prior Authorization

    Obtain precertification when Pre‑Payment Review program applies

    Precertification (prior authorization) is required for items and criteria referenced in this document for applicable local fully‑insured Anthem Blue Cross members and select ASO members when services are medically managed as part of a purchased program; providers will be notified upon requesting precertification if it is required for the member.

    • If the Pre‑Payment Review Program has not been purchased by the account, precertification is not required and clinical review will not be performed.
    Prior Authorization

    Reference indexed CG entries when requesting authorization

    The document indexes numerous Clinical Guideline (CG) entries and associated CG numbers that typically correspond to prior authorization policies; providers should reference the listed CG numbers when preparing authorization requests.

    • Examples of indexed CG entries appear throughout the listing (e.g., CC‑0174, CC‑0175, CC‑0187–CC‑0197, CC‑0200–CC‑0264).

    Step Therapy / Sequencing

    StepDescription
    1This document is an index listing many drug- and therapy-specific Clinical UM PPO guideline entries (examples: PCSK9 inhibitors, Brineura, Spinraza, Trogarzo, Krystexxa, many specialty biologics). Each listed Clinical Guideline (CG/CC number and title) is used to determine prior authorization/precertification requirements where the Pre-Payment Review Program or local plan requires it; specific step therapy rules, sequencing, and failure criteria are contained within the individual guideline documents referenced by CG/CC number.
    StepDescription
    0No explicit step therapy sequencing, mandatory trials, or step requirements are specified in this extract. The fragment only lists guideline titles and CG/CC numbers; where a guideline title contains 'Step Therapy' the detailed requirements must be retrieved from that specific guideline document.

    Site-of-Care Policies

    Billing Rule

    Infusion center — see CG‑MED‑83 Site of Care

    Site‑of‑care policies are referenced for specialty pharmaceuticals (see CG‑MED‑83 Site of Care: Specialty Pharmaceuticals); providers should consult that guideline for site‑of‑care rules applicable to infusion centers.

    Billing Rule

    Hospital outpatient — Carelon surgical site‑of‑care review applies for select accounts

    Carelon Surgical Procedures — Site‑of‑Care Review and related surgical procedure resources apply for select accounts; providers should reference the Carelon surgical site‑of‑care guideline and surgical procedure checklist when site‑of‑care review is required for hospital outpatient settings.

    Background & Purpose

    Background: this document is an index/listing of Clinical UM PPO guideline titles and control numbers used for California PPO. It identifies the scope of individual guideline documents (many are drug‑ or device‑specific) and notes administrative applicability: these listings govern precertification and utilization management when the account has purchased the Pre‑Payment Review or similar program. Carelon Medical Benefits Management guideline links are referenced for selected clinical appropriateness topics. The file clarifies exclusions for BlueCard®, Medicare Advantage, Medicaid, Medicare Supplement, and FEP® members and documents the biomarker testing prior authorization exemption for advanced or metastatic stage 3 or 4 cancer effective July 1, 2022.

    Definitions & Terms

    CG number — internal Clinical Guideline identifier
    CG number — definitionInternal Clinical Guideline identifier used by the payer to reference a drug‑specific or topic‑specific coverage guideline (e.g., CC‑0090).
    Format examplesPrefix and identifier formats appear as 'CC‑####' or 'CG‑CATEGORY‑##' in guideline listings.
    Use caseReferenced by providers when submitting precertification/prior authorization requests to identify the applicable guideline.
    Pre-Payment Review Program definition
    Pre-Payment Review Program — definitionA purchased program under which clinical guidelines are applied as part of pre‑payment review; when purchased, precertification may be required and clinical review performed.
    Effect on precertificationIf the program has not been purchased for an account, precertification is not required and clinical review will not be performed.
    Policy Summary
    PayerBlue Cross Blue Shield - Maine
    PolicyClinical UM PPO Guidelines (California) — index of clinical guideline entries
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain precertification (prior authorization) when required and contact the phone number on the member's ID card to confirm precertification requirements.
    SourceLink
    On This Page
    Coverage Criteria & ScopeClinical Guideline Index & CodesPrecertification, Prior Authorization & Provider NoticesStep Therapy / SequencingSite-of-Care PoliciesBackground & PurposeDefinitions & Terms
    Prior Authorization

    Use drug‑specific CGs to determine PA criteria

    Drug‑specific Clinical Guidelines (CG numbers and titles) listed in this document are the governing references used to determine precertification/prior authorization requirements for the named specialty drugs under California PPO plans.

    • Providers must use the drug‑specific CG title/number (as listed) to locate the detailed prior authorization criteria in the corresponding guideline document.
    Note

    Listed drug‑specific guidelines imply PA — consult each CG

    This fragment lists many drug‑specific CG titles and CG numbers (drug‑specific guideline entries) for California PPO; while the listing implies prior authorization, this extract does not include the explicit submission requirements or affected billing codes — providers must consult the individual CG for those details.

    • Listed examples include Danyelza (naxitamab‑gqgk), Oxlumo (lumasiran), Margenza (margetuximab‑cmkb), Breyanzi (lisocabtagene maraleucel).
    Prior Authorization

    Include CG number(s) on PA requests

    When submitting authorization requests, reference the CG number(s) provided in the index (e.g., CG‑MED‑19, CG‑MED‑34, CG‑SURG‑92 and many CC‑/CG‑ prefixed numbers) so the plan can apply the correct guideline during review.

    • Carelon Clinical Appropriateness guidelines are also cited with web links for specialty topics (cardiology, genetic testing, radiology, surgical site‑of‑care) and should be referenced when noted.
    Prior Authorization

    PA required for select accounts — provider will be notified

    Prior authorization review applies for select accounts using the Anthem Clinical UM Guideline and for certain Carelon guidelines; providers will be notified when requesting precertification if prior authorization is required for the member.

    • Applicability is limited to local fully‑insured and select ASO members when the employer/account has purchased the program.
    Step Therapy

    Check individual CGs for step therapy rules

    Many listed guideline entries may contain step therapy rules within their full guideline documents; this index does not enumerate those rules, so providers must review the individual CG for any step therapy requirements.

    • Some CG titles explicitly include 'Step Therapy' in the title (e.g., Rituximab Agents for Oncologic Indications Step Therapy), indicating sequencing rules exist in the referenced guideline.
    Note

    Titles including 'Step Therapy' indicate sequencing in that CG

    References to 'Step Therapy' appear as part of certain CG titles in the index, signaling that those specific guideline documents contain step therapy sequencing; the index itself does not provide the sequencing details.

    • When a CG title includes 'Step Therapy', follow that guideline's documented step failures and required trials for authorization.
    Note

    No summary provided

    No summary content was provided for this inventory item in the fragment; there are no actionable requirements in this placeholder entry.

    Step Therapy

    No step therapy rules present in this fragment

    This extract does not include step therapy rules or sequencing information; providers must review each referenced clinical guideline to determine whether step therapy applies.

    • The index lists many drug names and CG references but does not specify required prior agents, durations, or failure criteria.
    Step Therapy

    Step therapy — none specified in index

    The index provides no explicit step therapy requirements; absence of sequencing in the extract means providers should consult the full CG documents for any step therapy policies.

    Step Therapy

    No step therapy details available

    No step therapy operational details (such as required trials, durations, or failure criteria) are present in these chunks; the index only identifies which guidelines to consult.

    Documentation Required

    Contact member ID back‑of‑card phone to confirm precertification

    For information about precertification requirements or to confirm whether precertification is required for a specific member, providers should call the phone number on the back of the member's ID card; the provider will also be notified upon requesting precertification if it is required.

    • If the account has not purchased the Pre‑Payment Review Program, precertification is not required and clinical review will not be performed.
    Documentation Required

    No documentation requirements in index — consult individual CGs

    This index portion does not contain documentation or submission requirements; it primarily lists CG numbers, guideline titles, and occasional implementation dates — providers must refer to individual CGs for documentation needed for authorization.

    Documentation Required

    Provider will be notified upon requesting precertification

    When a provider requests precertification, the plan will notify whether precertification is required for the member; contact information is available on the member ID card.

    • Notification upon request is the mechanism for confirming whether a purchased program requires precertification for that member.
    Documentation Required

    No submission or documentation instructions in this extract

    This fragment does not include documentation or submission instructions (forms, supporting clinical data, or billing codes); providers should obtain those requirements from the individual CG or the precertification contact.

    Prior Authorization

    Do not require PA for biomarker testing in stage 3–4 cancer; confirmation allowed

    Confirmation of advanced or metastatic stage 3 or 4 cancer is permitted for post‑service review of biomarker testing, but effective July 1, 2022, prior authorization will no longer be required for biomarker testing for members with advanced or metastatic stage 3 or 4 cancer; post‑service medical necessity review for those members is not permitted except to confirm stage.

    • This change is effective July 1, 2022, per California SB 535 compliance noted in the guideline.
    Denial Risk

    Missing precertification may lead to administrative denial when program purchased

    If precertification is required and not obtained for a member covered under a purchased Pre‑Payment Review Program, lack of required precertification may trigger administrative denial or notification; conversely, if the program has not been purchased by the account, precertification is not required and clinical review will not be performed.

    • Providers will be notified upon requesting precertification whether precertification is required for the member.
    Denial Risk

    No explicit denial triggers in index — consult CGs

    This fragment is an index of CG numbers and titles and does not state explicit denial triggers; providers must refer to each clinical guideline for specific authorization triggers and denial criteria.

    Note

    Precertification not required if program not purchased by account

    If the account has not purchased the Pre‑Payment Review Program (for example, a prior authorization program), precertification is not required and clinical review will not be performed; providers will be notified when requesting precertification if the program applies to the member.

    Note
    Note
    Note
    Note
    Provider notificationProviders will be notified upon requesting precertification if precertification is required for the member; contact the phone number on the member ID card for details.
    CG number / CG title definition
    CG number / CG title — definitionClinical Guideline identifier (CG‑*) paired with an associated title that indicates the policy topic (for example, CG‑MED‑19 Custodial Care).
    PurposeUsed to locate the specific guideline document that governs coverage, utilization management, and prior authorization for the named service or drug.
    Examples in documentMultiple entries listed (e.g., CG‑MED‑19, CG‑MED‑64, CG‑SURG‑71) with original and current implementation dates where provided.
    Carelon Medical Benefits Management, Inc. — definition/role
    Carelon Medical Benefits Management, Inc. — roleAn independent company providing Clinical Appropriateness Guidelines and select utilization management services on behalf of the health plan.
    Guideline availabilityCarelon guideline webpages are cited for specialty topics (cardiology, genetic testing, musculoskeletal, surgical site‑of‑care, radiation oncology, etc.).
    Account applicabilityFor certain health plan members, Carelon also provides select utilization management services and authorization review for select accounts.